A hybrid guide RNA (hgRNA) comprising a proximal spacer, a distal spacer, a type II CRISPR-Cas tracrRNA, and a type V CRISPR-Cas direct repeat. Also provided herein are further multiplexed hgRNAs comprising additional direct repeats and spacers as well as methods of making and using thereof. Libraries comprising said hgRNAs or components thereof, cells, kits and reagents employed in the making or use thereof are also provided.

Methods of normalizing two or more nucleic acid samples are provided. Aspects of the methods include contacting each of the two or more nucleic acid samples with a limiting amount of a target binding moiety that specifically binds to a common target in each of the two or more nucleic acid samples to produce binding complexes in each of the two or more nucleic acid samples; and separating the binding complexes from unbound nucleic acids in each of the two or more nucleic acid samples to normalize the two or more nucleic acid samples. Compositions and kits for use in performing the methods are also provided.

De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.

The present invention discloses a profiling technique for a target molecule population in a sample including an unknown target molecule, using an aptamer. In the method of the present invention, the target molecule population in the sample may be provided as an aptamer profile including an unknown target molecule, and this aptamer profile can be used to determine whether drug prescription is appropriate (i.e., anticancer drug companion diagnosis, etc.), to provide disease diagnosis information, to monitor drug treatment, to determine drug compliance, to determine the degree or absence/presence of in vitro cellular response to drug treatment, and to obtain useful information to humans for classification or identification of species, etc.

Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.

Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.

Methods of analyzing cells, including interactions among different populations of cells. Methods include cell-containing liquid droplets with oligonucleotide-containing liquid droplets, hybridizing oligonucleotides to target nucleic acids from cells, extending the hybridized oligonucleotides on the target nucleic acids into cell identifier sequences on the target nucleic acids, and thereby identifying the type of cells initially present. The methods can be implemented in a high-throughput manner in a microfluidic system.

The present disclosure provides a kit for preparing a library of nucleic acids. The kit includes first and second oligonucleotide, each having a tail sequence, a common sequence, and at least one of a unique identifier sequence, and a variable length punctuation mark. The kit further includes a first primer having a first sample identifier sequence and a first priming sequence at a 3′ end of the first primer. The first priming sequence includes the tail sequence of the first oligonucleotide. The kit further includes a second primer having a second sample identifier sequence and a second priming sequence at a 3′ end of the second primer. The second priming sequence is complimentary to the second tail sequence of the second oligonucleotide.

Provided herein is technology relating to microarrays and particularly, but not exclusively, to microarray devices and systems, methods for producing microarrays, and methods of using microarrays.

Provided herein is technology relating to microarrays and particularly, but not exclusively, to microarray devices and systems, methods for producing microarrays, and methods of using microarrays.